Works by Heise, Tim
Results: 126
A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage.
- Published in:
- Frontiers in Aging, 2022, p. 1, doi. 10.3389/fragi.2022.852569
- By:
- Publication type:
- Article
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
- Published in:
- Clinical Diabetes & Endocrinology, 2021, v. 7, n. 1, p. 1, doi. 10.1186/s40842-021-00130-x
- By:
- Publication type:
- Article
Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 9, p. 885, doi. 10.1007/s40261-017-0539-7
- By:
- Publication type:
- Article
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
- Published in:
- Clinical Drug Investigation, 2017, v. 37, n. 5, p. 503, doi. 10.1007/s40261-017-0499-y
- By:
- Publication type:
- Article
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2023, v. 46, n. 5, p. 998, doi. 10.2337/dc22-1710
- By:
- Publication type:
- Article
Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Sustained Intensive Treatment and Long-term Effects on HbA<sub>1c</sub> Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Association Between HbA<sub>1c</sub> and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.
- Published in:
- 2016
- By:
- Publication type:
- journal article
New Insulin Glargine 300 Units⋅mL<sup>-1</sup> Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units⋅mL<sup>-1</sup>.
- Published in:
- Diabetes Care, 2015, v. 38, n. 4, p. 637, doi. 10.2337/dc14-0006
- By:
- Publication type:
- Article
Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 12, p. 2626, doi. 10.2337/dc12-0270
- By:
- Publication type:
- Article
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2011, v. 34, n. 3, p. 669, doi. 10.2337/dc10-1905
- By:
- Publication type:
- Article
Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2010, v. 33, n. 6, p. 1288, doi. 10.2337/dc09-1807
- By:
- Publication type:
- Article
Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy.
- Published in:
- Diabetes Care, 2009, v. 32, n. 8, p. 1431, doi. 10.2337/dc09-0097
- By:
- Publication type:
- Article
Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region.
- Published in:
- Clinical Drug Investigation, 2014, v. 34, n. 9, p. 673, doi. 10.1007/s40261-014-0218-x
- By:
- Publication type:
- Article
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2010, v. 95, n. 11, p. 5028, doi. 10.1210/jc.2010-1041
- By:
- Publication type:
- Article
Absence of a glucose‐lowering effect in glucose clamp procedures with a long‐acting insulin analogue.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 12, p. 6067, doi. 10.1111/dom.15939
- By:
- Publication type:
- Article
Back Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. C4, doi. 10.1111/dom.16055
- By:
- Publication type:
- Article
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4639, doi. 10.1111/dom.15827
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1941, doi. 10.1111/dom.15510
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU‐ und US‐sourced reference insulins.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3817, doi. 10.1111/dom.15281
- By:
- Publication type:
- Article
Cover Image.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1, doi. 10.1111/dom.15067
- By:
- Publication type:
- Article
A co‐formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short‐term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1241, doi. 10.1111/dom.14972
- By:
- Publication type:
- Article
Oral insulin: A history of ambition, failure and data torturing.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 940, doi. 10.1111/dom.14984
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1080, doi. 10.1111/dom.14956
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 832, doi. 10.1111/dom.14932
- By:
- Publication type:
- Article
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1689, doi. 10.1111/dom.14773
- By:
- Publication type:
- Article
ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 4, p. 961, doi. 10.1111/dom.14302
- By:
- Publication type:
- Article
Cover Image, Volume 23, Issue 3.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 4, p. 1, doi. 10.1111/dom.14378
- By:
- Publication type:
- Article
The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD‐5).
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 619, doi. 10.1111/dom.14257
- By:
- Publication type:
- Article
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 10, p. 1789, doi. 10.1111/dom.14094
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 521, doi. 10.1111/dom.13919
- By:
- Publication type:
- Article
Better glycaemic control with BioChaperone glargine lispro co‐formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 7, p. 1570, doi. 10.1111/dom.13685
- By:
- Publication type:
- Article
BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 1066, doi. 10.1111/dom.13621
- By:
- Publication type:
- Article
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 601, doi. 10.1111/dom.13562
- By:
- Publication type:
- Article
Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 569, doi. 10.1111/dom.13555
- By:
- Publication type:
- Article
Ultra‐rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14‐day crossover treatment study in people with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 11, p. 2627, doi. 10.1111/dom.13442
- By:
- Publication type:
- Article
Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1140, doi. 10.1111/dom.13203
- By:
- Publication type:
- Article
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/ mL in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 1032, doi. 10.1111/dom.12938
- By:
- Publication type:
- Article
Novel hepato-preferential basal insulin peglispro ( BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 482, doi. 10.1111/dom.12834
- By:
- Publication type:
- Article
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 489, doi. 10.1111/dom.12838
- By:
- Publication type:
- Article
Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 2, p. 208, doi. 10.1111/dom.12803
- By:
- Publication type:
- Article
Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 33, doi. 10.1111/dom.12759
- By:
- Publication type:
- Article
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 3, doi. 10.1111/dom.12782
- By:
- Publication type:
- Article
Euglycaemic glucose clamp: what it can and cannot do, and how to do it.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 10, p. 962, doi. 10.1111/dom.12703
- By:
- Publication type:
- Article
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
- Published in:
- 2017
- By:
- Publication type:
- journal article